Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

GlobeNewswire October 15, 2021

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire September 3, 2021

Royalty Pharma Reports Second Quarter 2021 Results

GlobeNewswire August 11, 2021

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

GlobeNewswire July 19, 2021

Royalty Pharma Declares Third-Quarter 2021 Dividend

GlobeNewswire July 16, 2021

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

GlobeNewswire July 15, 2021

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire June 7, 2021

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

GlobeNewswire June 2, 2021

Royalty Pharma Reports First Quarter 2021 Results

GlobeNewswire May 11, 2021

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire May 7, 2021

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

GlobeNewswire April 21, 2021

Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

GlobeNewswire April 21, 2021

Royalty Pharma Acquires OXLUMO(TM) Royalty Interest From Dicerna for up to $240 Million

GlobeNewswire April 8, 2021

Dicerna Sells OXLUMO(TM) (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

Business Wire April 8, 2021

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK

GlobeNewswire April 1, 2021

Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director

GlobeNewswire March 30, 2021

Royalty Pharma Reports Q4 2020 and Full-Year Results

GlobeNewswire February 17, 2021

Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021

GlobeNewswire January 22, 2021

Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences

GlobeNewswire January 19, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

GlobeNewswire January 19, 2021